337 related articles for article (PubMed ID: 36132858)
21. The effects of protein corona on in vivo fate of nanocarriers.
Xiao Q; Zoulikha M; Qiu M; Teng C; Lin C; Li X; Sallam MA; Xu Q; He W
Adv Drug Deliv Rev; 2022 Jul; 186():114356. PubMed ID: 35595022
[TBL] [Abstract][Full Text] [Related]
22. In Situ Characterization of Protein Adsorption onto Nanoparticles by Fluorescence Correlation Spectroscopy.
Shang L; Nienhaus GU
Acc Chem Res; 2017 Feb; 50(2):387-395. PubMed ID: 28145686
[TBL] [Abstract][Full Text] [Related]
23. The Nano-Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions.
Wang Y; Cai R; Chen C
Acc Chem Res; 2019 Jun; 52(6):1507-1518. PubMed ID: 31149804
[TBL] [Abstract][Full Text] [Related]
24. Impact of Protein Corona on the Biological Identity of Nanomedicine: Understanding the Fate of Nanomaterials in the Biological Milieu.
Akhter MH; Khalilullah H; Gupta M; Alfaleh MA; Alhakamy NA; Riadi Y; Md S
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680613
[TBL] [Abstract][Full Text] [Related]
25. Formation of a protein corona influences the biological identity of nanomaterials.
Nierenberg D; Khaled AR; Flores O
Rep Pract Oncol Radiother; 2018; 23(4):300-308. PubMed ID: 30100819
[TBL] [Abstract][Full Text] [Related]
26. Core, Coating, or Corona? The Importance of Considering Protein Coronas in nano-QSPR Modeling of Zeta Potential.
Sengottiyan S; Mikolajczyk A; Jagiełło K; Swirog M; Puzyn T
ACS Nano; 2023 Feb; 17(3):1989-1997. PubMed ID: 36651824
[TBL] [Abstract][Full Text] [Related]
27. Does the protein corona take over the selectivity of molecularly imprinted nanoparticles? The biological challenges to recognition.
Capriotti A; Piovesana S; Zenezini Chiozzi R; Montone CM; Bossi AM; Laganà A
J Proteomics; 2020 May; 219():103736. PubMed ID: 32198073
[TBL] [Abstract][Full Text] [Related]
28. The Janus of Protein Corona on nanoparticles for tumor targeting, immunotherapy and diagnosis.
Wang X; Zhang W
J Control Release; 2022 May; 345():832-850. PubMed ID: 35367478
[TBL] [Abstract][Full Text] [Related]
29. Biological Features of Nanoparticles: Protein Corona Formation and Interaction with the Immune System.
Panico S; Capolla S; Bozzer S; Toffoli G; Dal Bo M; Macor P
Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559099
[TBL] [Abstract][Full Text] [Related]
30. Protein corona: Dr. Jekyll and Mr. Hyde of nanomedicine.
Fasoli E
Biotechnol Appl Biochem; 2021 Dec; 68(6):1139-1152. PubMed ID: 33007792
[TBL] [Abstract][Full Text] [Related]
31. In Situ Characterization of the Protein Corona of Nanoparticles In Vitro and In Vivo.
Latreille PL; Rabanel JM; Le Goas M; Salimi S; Arlt J; Patten SA; Ramassamy C; Hildgen P; Martinez VA; Banquy X
Adv Mater; 2022 Sep; 34(38):e2203354. PubMed ID: 35901787
[TBL] [Abstract][Full Text] [Related]
32. Physicochemical properties determine nanomaterial cellular uptake, transport, and fate.
Zhu M; Nie G; Meng H; Xia T; Nel A; Zhao Y
Acc Chem Res; 2013 Mar; 46(3):622-31. PubMed ID: 22891796
[TBL] [Abstract][Full Text] [Related]
33. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery.
Corbo C; Molinaro R; Parodi A; Toledano Furman NE; Salvatore F; Tasciotti E
Nanomedicine (Lond); 2016 Jan; 11(1):81-100. PubMed ID: 26653875
[TBL] [Abstract][Full Text] [Related]
34. Distinct Proteins in Protein Corona of Nanoparticles Represent a Promising Venue for Endogenous Targeting - Part I: In vitro Release and Intracellular Uptake Perspective.
Sebak AA; Gomaa IEO; ElMeshad AN; Farag MH; Breitinger U; Breitinger HG; AbdelKader MH
Int J Nanomedicine; 2020; 15():8845-8862. PubMed ID: 33204091
[TBL] [Abstract][Full Text] [Related]
35. Understanding the Factors Influencing Chitosan-Based Nanoparticles-Protein Corona Interaction and Drug Delivery Applications.
Moraru C; Mincea M; Menghiu G; Ostafe V
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081296
[TBL] [Abstract][Full Text] [Related]
36. Modulating the toxicity of engineered nanoparticles by controlling protein corona formation: Recent advances and future prospects.
Wang J; Xu Y; Zhou Y; Zhang J; Jia J; Jiao P; Liu Y; Su G
Sci Total Environ; 2024 Mar; 914():169590. PubMed ID: 38154635
[TBL] [Abstract][Full Text] [Related]
37. Unraveling the Effect of Breast Cancer Patients' Plasma on the Targeting Ability of Folic Acid-Modified Chitosan Nanoparticles.
Nemati M; Bani F; Sepasi T; Zamiri RE; Rasmi Y; Kahroba H; Rahbarghazi R; Sadeghi MR; Wang Y; Zarebkohan A; Gao H
Mol Pharm; 2021 Dec; 18(12):4341-4353. PubMed ID: 34779630
[TBL] [Abstract][Full Text] [Related]
38. Understanding the Nano-Bio Interactions and the Corresponding Biological Responses.
Tian X; Chong Y; Ge C
Front Chem; 2020; 8():446. PubMed ID: 32587847
[TBL] [Abstract][Full Text] [Related]
39. Quantitative comparison of the protein corona of nanoparticles with different matrices.
Ottonelli I; Duskey JT; Genovese F; Pederzoli F; Caraffi R; Valenza M; Tosi G; Vandelli MA; Ruozi B
Int J Pharm X; 2022 Dec; 4():100136. PubMed ID: 36304137
[TBL] [Abstract][Full Text] [Related]
40. How Entanglement of Different Physicochemical Properties Complicates the Prediction of in Vitro and in Vivo Interactions of Gold Nanoparticles.
Xu M; Soliman MG; Sun X; Pelaz B; Feliu N; Parak WJ; Liu S
ACS Nano; 2018 Oct; 12(10):10104-10113. PubMed ID: 30212621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
